6533b7cffe1ef96bd1258669
RESEARCH PRODUCT
The global impact of the COVID-19 pandemic on the management and course of chronic urticaria
Emek KocatürkAndaç SalmanIvan Cherrez-ojedaPaulo Ricardo CriadoJonny PeterElif Comert-ozerMohamed AbuzakoukRosana Câmara AgondiMona Al-ahmadSabine AltrichterRand ArnaoutLuisa Karla ArrudaRiccardo AseroAndrea BauerMoshe Ben-shoshanJonathan BernsteinMojca BizjakIsabelle Boccon-gibodHanna BonnekohLaurence BouilletZenon BrzozaPaula BusseRegis A. CamposEmily CarneNiall ConlonRoberta Fachini Jardim CriadoEduardo Magalhães De Souza LimaSemra DemirJoachim DissemondSibel Doğan GünaydınIrina DorofeevaLuis Felipe EnsinaRagip ErtaşSilvia Mariel FerrucciIgnasi Figueras-nartDaria FominaSylvie M. FrankenAtsushi FukunagaAna M Giménez ArnauKiran GodseMargarida GonçaloMaia GotuaClive GrattanCarole GuilletNaoko InomataThilo JakobGul KarakayaAlicja Kasperska-zającConstance H. KatelarisMitja KošnikDorota KrasowskaKanokvalai KulthananM.sendhil KumaranClaudia LangJosé Ignacio Larco-sousaElisavet LazaridouTabi Anika LeslieUndine LippertOscar Calderón LlosaMichael MakrisAlexander MarslandIris V. MedinaRaisa MeshkovaEsther Bastos PalitotClaudio A.s. ParisiJulia PickertGermán D. RamonMónica Rodríguez-gonzalezNelson RosarioMichael RudenkoKrzysztof RutkowskiJorge Mario Sánchez CaraballoSibylle SchliemannBulent Enis SekerelFaradiba S. SerpaE Serra-baldrichZhiqiang SongAngèle SoriaMaria StaevskaPetra StaubachAnna TagkaShunsuke TakahagiSimon Francis ThomsenRegina TreudlerZahava VadaszSolange Oliveira Rodrigues ValleMartijn B.a. Van DoornChristian VestergaardNicola WagnerDahu WangLiangchun WangBettina WediParaskevi XepapadakiEsra YücelAnna Zalewska-janowskaZuotao ZhaoTorsten ZuberbierMarcus MaurerUniversitat Autònoma De Barcelonasubject
Male0301 basic medicineSTRESSExacerbationUCAREpandemijeMedizinOmalizumabOmalizumabSERUMchronic urticaria0302 clinical medicinePandemicHealth careImmunology and AllergyChronic UrticariatreatmentChronic urticaria; COVID-19; Cyclosporine; Omalizumab; Pandemic; SARS-CoV-2; Treatment; UCAREzdravljenjeASSOCIATIONMiddle AgedCOVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatmentkronična urtikarijaINFECTIONSGA(2)LENCyclosporineFemale600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drugAdultmedicine.medical_specialtyAdolescentCoronavirus disease 2019 (COVID-19)Immunology610udc:616-097pandemicsciklosporinYoung Adult03 medical and health sciencesPatient referralmedicineHumansIn patientPatient Reported Outcome MeasurescyclosporineChronic urticariaAgedInternetPandemicSARS-CoV-2business.industrypandemicCOVID-19TreatmentDEFINITIONMedicine; Allergy; ImmunologyCross-Sectional Studies030104 developmental biology030228 respiratory systemEmergency medicineomalizumabbusinessdescription
Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-03-01 | Allergy: European Journal of Allergy and Clinical Immunology |